Compare Msci Inc (MSCI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Msci Inc trades at $565.12 (market cap $40.38B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Msci Inc is far larger — about 4× State Street SPDR S&P Biotech ETF's market cap, and Msci Inc pays a 1.48% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MSCI | XBI | |
|---|---|---|
Market Cap | $40.38B | $10.11B |
Volume | 414,140 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $643.83 | $169.55 |
52-Week Low | $511.84 | $104.99 |
Typical Hold Time | 82 Days | 38 Days |
Enterprise Value | $46.54B | — |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $561.67, up 1.13% in 24 hours, with a bullish technical signal and strong fundamental performance. The stock has exceeded earnings expectations in recent quarters, with Q3 2026 results pending. Revenue growth is steady, supported by high profit margins and recurring subscription income. Recent news highlights the completion of the First Street acquisition and upcoming earnings call, reinforcing positive business momentum.
The outlook for MSCI remains favorable, driven by robust earnings, analyst consensus of a buy rating, and a price target implying significant upside. Key risks include high valuation multiples and market sensitivity to financial services demand. Investors should weigh strong profitability against potential volatility from economic cycles.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
